Latest filings (excl ownership)
15-12B
Securities registration termination
18 Dec 17
25-NSE
Exchange delisting
8 Dec 17
8-K
KKR Completes Acquisition of PharMerica
7 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Dec 17
10-Q
2017 Q3
Quarterly report
9 Nov 17
8-K
Pharmerica Reports Third Quarter 2017 Results
9 Nov 17
8-K
PharMerica Announces Approval of Merger by Stockholders
9 Nov 17
8-K
Other Events
27 Oct 17
DEFA14A
Additional proxy soliciting materials
27 Oct 17
DEFM14A
Proxy related to merger
3 Oct 17
PREM14A
Preliminary proxy related to merger
6 Sep 17
8-K
Other Events
28 Aug 17
DEFA14A
Additional proxy soliciting materials
28 Aug 17
8-K
Entry into a Material Definitive Agreement
3 Aug 17
DEFA14A
Additional proxy soliciting materials
3 Aug 17
10-Q
2017 Q2
Quarterly report
2 Aug 17
8-K
Pharmerica Reports Second Quarter 2017 Results
2 Aug 17
8-K
PharMerica Corporation Enters into Definitive Agreement to Be Acquired by KKR for $29.25 per Share in Cash
2 Aug 17
DEFA14A
Additional proxy soliciting materials
2 Aug 17
DEFA14A
Additional proxy soliciting materials
2 Aug 17
8-K
Submission of Matters to a Vote of Security Holders
19 Jun 17
10-Q
2017 Q1
Quarterly report
10 May 17
8-K
Pharmerica Reports First Quarter 2017 Results
10 May 17
DEF 14A
Definitive proxy
1 May 17
8-K
Departure of Directors or Certain Officers
21 Apr 17
8-K
Amendments to Articles of Incorporation or Bylaws
30 Mar 17
8-K
Pharmerica Reports Fourth Quarter and Full Year 2016 Results
27 Feb 17
10-K
2016 FY
Annual report
24 Feb 17
8-K
PharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer
1 Feb 17
UPLOAD
Letter from SEC
19 Dec 16
8-K
Entry into a Material Definitive Agreement
15 Dec 16
CORRESP
Correspondence with SEC
15 Dec 16
UPLOAD
Letter from SEC
2 Dec 16
CORRESP
Correspondence with SEC
14 Nov 16
10-Q
2016 Q3
Quarterly report
9 Nov 16
8-K
Pharmerica Reports Third Quarter 2016 Results
9 Nov 16
UPLOAD
Letter from SEC
31 Oct 16
8-K
Termination of a Material Definitive Agreement
10 Aug 16
Latest ownership filings
SC 13G/A
PharMerica CORP
13 Feb 18
SC 13G/A
PharMerica CORP
9 Feb 18
4
GREGORY S WEISHAR
11 Dec 17
4
Suresh Vishnubhatla
8 Dec 17
4
ROBERT A OAKLEY
8 Dec 17
4
Berard Tomassetti
8 Dec 17
4
PATRICK G LEPORE
8 Dec 17
4
Thomas A Caneris
8 Dec 17
4
FRANK E COLLINS
8 Dec 17
4
GEOFFREY G MEYERS
8 Dec 17
4
Robert A McKay
8 Dec 17
4
MARJORIE W DORR
8 Dec 17
4
Robert E. Dries
8 Dec 17
4
W Robert Dahl Jr
8 Dec 17
4
Robert A McKay
21 Nov 17
4
PATRICK G LEPORE
16 Jun 17
4
ROBERT A OAKLEY
16 Jun 17
4
MARJORIE W DORR
16 Jun 17
4
W Robert Dahl Jr
16 Jun 17
4
GEOFFREY G MEYERS
16 Jun 17
4
FRANK E COLLINS
16 Jun 17
4
Robert A McKay
11 Apr 17
4
Suresh Vishnubhatla
11 Apr 17
4
GREGORY S WEISHAR
11 Apr 17
4
Berard Tomassetti
11 Apr 17
4
Thomas A Caneris
11 Apr 17
4
Robert A McKay
28 Mar 17
4
Thomas A Caneris
28 Mar 17
4
Berard Tomassetti
28 Mar 17
4
Suresh Vishnubhatla
28 Mar 17
4
GREGORY S WEISHAR
28 Mar 17
4
Thomas A Caneris
21 Mar 17
4
Suresh Vishnubhatla
21 Mar 17
4
Robert A McKay
21 Mar 17
4
Berard Tomassetti
21 Mar 17
4
GREGORY S WEISHAR
21 Mar 17
4
GREGORY S WEISHAR
17 Mar 17
4
GREGORY S WEISHAR
15 Mar 17
4
Robert A McKay
15 Mar 17
4
Suresh Vishnubhatla
15 Mar 17